Basic Information
ID DDInter1347 and DDInter9
Interaction Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme.
Management The potential for diminished pharmacologic effects of acalabrutinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
References [1] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. [2] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Alternative for Oritavancin J01X
Tinidazole Linezolid Bacitracin Polymyxin B Daptomycin Vancomycin
Metronidazole Telavancin Methenamine Spectinomycin Nitrofurantoin
More
Alternative for Acalabrutinib L01E
Pralsetinib Dabrafenib Asciminib Dacomitinib Pexidartinib Pacritinib
Fedratinib Bosutinib Vandetanib Cobimetinib Ibrutinib
More
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.